Chinese exiled dissident community stunned by loss of murdered New York lawyer

Police in New York have arrested a 25-year-old woman in connection with the stabbing to death of a former 1989 Tiananmen Square protester, who worked as an immigration lawyer after fleeing China at the end of the two-year jail term for joining the pro-democracy protests.

Li Jinjin, 67, who played a key role while a student in the 1989 protests, was stabbed to death on March 14.

Police have arrested Zhang Xiaoning, who faces charges of homicide and unlawful possession of a weapon, they said in a statement. Queens District Attorney Melinda Katz will lead the prosecution.

Zhao Yan, a current affairs commentator with knowledge of the case, said there are concerns in Chinese émigré and dissident circles in the U.S. that Zhang, a student who was very active in exile pro-democracy groups, wasn’t everything she appeared.

While Zhang had arrived in the U.S. in August 2021 on an F-1 student visa, she hadn’t enrolled at any school, instead spending most of her time in pro-democracy activities among exiled Chinese dissidents.

Zhao said the type of injuries Li sustained during the attack suggested his assailant had received “professional training.”

He said Li would be sorely missed.

“Jinjin said he would help [a person] who was in a car accident for free, because they didn’t have the financial resources to file a lawsuit,” Zhao said. “Everyone knows that he would help people unconditionally.”

“He would go to the police stations to bail people out if they got arrested; he did a lot of work like that,” he said. “He was very kind, and a good friend, and what happened to him makes me very sad.”

‘An irreparable loss’

Exiled Chinese dissident Wang Juntao said he had known Li for more than three decades as both a colleague and a close friend.

“I really can’t believe that there’ll be no more Li Jinjin … in the future,” Wang said. “It really is an irreparable loss for all of us.”

He said Li was a passionate political activist in the overseas pro-democracy movement, who would debate political issues with the same fierceness as someone still in college.

“His departure has left a huge hold in the democracy movement, because he was in leading roles in several different groups over a long period of time,” Wang said. “He also handled all of their legal affairs.”

Wang said people had raised questions about Zhang Xiaoning’s identity after noting “paranoid and capricious” behavior on her part.

He said Li’s murder took place shortly after he had told Zhang to stop coming to his office, and threatened to drop her political asylum case.

Lawyer Zhu Wei said he found Li’s death “very hard to accept.”

“He is a very kind, honest and professional lawyer who had helped many people who came from China … much of it on a voluntary, pro bono basis,” Zhu said.

Spirits of Tiananmen

Hu Ping, honorary editor-in-chief of the U.S.-based pro-democracy magazine Beijing Spring, tweeted his condolences, sharing a long essay penned by Li on the 20th anniversary of the June 4, 1989 massacre of civilians by the People’s Liberation Army (PLA) that put an end to weeks of protests on Tiananmen Square.

In it, Li says the CCP has continued to claim that the protests were the work of “counterrevolutionary” thugs.

“The position of the Chinese government since the massacre has prevented full disclosure about what really happened,” Li wrote. “The victims are still referred to as thugs and their spirits have yet to be laid to rest.”

“The injured … have received no compensation to this day.”

Writer Bei Ming said Li was a “treasure” of the exiled pro-democracy movement, describing him as a serious and open-minded person with a zest for life.

Dozens of other fellow exiled dissidents penned an obituary for Li, praising his belief in the democracy movement, and his personal generosity.

“Li Jinjin’s greatest wish was to end the tyranny of the CCP,” the obituary concluded.

Li served two years’ imprisonment in the wake of the 1989 student-led pro-democracy movement, before going to the U.S. to study law in the 1990s.

He had practiced as an attorney in New York ever since.

Translated and edited by Luisetta Mudie.

Taiwan holds live-fire military drills on islands close to mainland

Taiwan held live-fire drills Wednesday on two of its islands not far from mainland China, part of a series of exercises to be held to boost combat readiness.

Media sources said more military drills are being planned this month by the Taiwanese military, including at the Pratas islands (also known as Dongsha) in the South China Sea.

According to the Taiwanese Ministry of National Defense, live-fire drills took place at dawn in Dongyin and Penghu – two of Taiwan’s outlying islets very close to mainland China.

Dongyin is part of the Matsu archipelago, 50 kilometers (30 miles) east of China’s Fujian province. It is about 185 kilometers (115 miles) northwest of Taiwan mainland.

The Matsu islands have been under Taiwan’s control since the end of the Chinese Civil War in 1949.

Dongyin is Taiwan’s northernmost point and the “most strategically important outlying island,” according to Sheu Jyh-Shyang, a military expert at the Taiwan’s Institute for National Defence and Security Research.

The island, despite being open to tourists, is heavily fortified with cruise missiles including Taiwan’s homegrown Hsiung Feng II anti-ship missiles and Sky Bow II surface-to-air anti-ballistic missiles.

It is also important for reconnaissance as “it is close enough to China to detect aircraft and vessels,” said Sheu.

Dongyin is also vulnerable to attacks both from the west and the south due to its proximity to China. It was in fact often shelled by China during the late 1970s.

The Taiwanese defense ministry confirmed that on Feb. 5 a Chinese Y-12 light twin-engine civilian aircraft flew closely to Dongyin but did not enter Taiwan’s air space.

‘Loyalty exercise’

Ian Easton, senior director at the Project 2049 Institute, a U.S. think-tank, said at that time that the flyby was “classic political warfare.”

“Chinese authorities sent a civilian aircraft over one of the most dangerous and heavily fortified islands on the planet,” Easton wrote on Twitter.

 “If Taiwan shoots, it provokes an armed response. If Taiwan shows restraint (which it did), it looks and feels weak.”

The Dongyin live-fire drills, named “Loyalty exercise,” took place amid concerns about China’s possible opportunistic moves in the region as the Ukrainian war is raging.

On March 10, Taiwan’s Minister of National Defense Chiu Kuo-Cheng warned the legislature’s Foreign Affairs and National Defense Committee that “there are similarities between the situation in Ukraine and Taiwan.”

Chiu, however, was quoted as saying that Taiwan has “a geographic advantage, as the Taiwan Strait is a maritime barrier that is risky to cross.”

According to Taiwan’s military, the drills on Dongyin included both anti-aircraft and anti-ship exercises.

Another live-fire exercise took place early Wednesday morning on Penghu island in the Taiwan Strait. Penghu is 181 kilometers (112 miles) from Xiamen, China. The drills focused on artillery with cannons and M60A3 Chariot tanks.

The Taiwanese coastguard was quoted by the Hong Kong newspaper South China Morning Post as saying that it would stage “annual live-fire drills on March 26 and 31” on Pratas island.

The Taiwanese defense ministry when asked by RFA did not confirm the event.

The Pratas island is located in the northern part of the South China Sea and is the largest of the South China Sea islands. It is claimed by both Taiwan and the People’s Republic of China, but has been under Taiwan’s control since 1946.

Philips PACS interoperability helps Scotland’s National Health Service deliver leading breast cancer screening

March 16, 2022

  • Philips Vue PACS interoperability enhances access, quality of care, and patient experience in Scottish Breast Screening Program 
  • Image sharing across regional breast screening centers helps better manage the post COVID-19 backlog of screening appointments

Amsterdam, the Netherlands and Orlando, Florida, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and NHS National Services Scotland, a non-departmental public body that provides advice and services to National Health Service (NHS) Scotland, today revealed the impact of the COVID-19 pandemic on the Scottish Breast Screening Program (SBSP), and the measures taken to deal with the backlog of delayed appointments. Philips’ vendor-neutral Vue PACS (Picture Archiving and Communication System) allows the SBSP’s six breast screening centers and its mobile screening units to interoperate with Scotland’s national PACS system, increasing access to breast screening for Scotland’s rural communities, enhancing patient choice, and streamlining diagnostic and treatment workflows.

Female breast cancer is the world’s most common form of cancer, with approximately 2.26 million new cases in 2020 [1]. Nearly 1,000 women per year die from the disease in Scotland alone [2]. Through the partnership between Philips and NHS National Services Scotland, as many as 270,000 women in Scotland between the ages of 50 and 70 are invited for breast screening (mammography) every year [3]. However, according to Public Health Scotland (PHS), between April 2020 and December 2020 during the height of the COVID-19 pandemic, there was a 19% fall in the number of women diagnosed with early-stage breast cancer (down 35% at stage 1 and 15% at stage 2 diagnosis) [4]. This drop was largely attributed to the SBSP being paused between March 30 and August 3, 2020, creating a backlog of appointments, diagnoses, and treatments.

Philips Picture Archiving and Communication System (Vue PACS) is a scalable and modular image management solution that provides hospitals and related institutions with scalable (local and wide area) PACS functionalities. The interoperability of Philips’ Vue PACS has been a key factor in reducing that backlog, offering enhanced connectivity between the screening program’s regional screening centers, as well as interoperability with Scotland’s Global PACS system.

“The national reporting function enabled by the Global PACS solution allows centers to report and support each other. For instance, in the case of a staffing issue due to absences from sickness amongst readers, cases for reporting can rapidly pile up. The use of this function allows readers from across Scotland to provide mutual aid and assistance in ensuring all centers are at a similar level in reporting,” said Dr. Gerald Lip, Clinical Director of NE Scotland Breast Screening Service.

Streamlining workflows, improving access to better care
The interoperability of Philips Vue PACS with Scotland’s Global PACS system makes an individual patient’s current and prior mammography images available to all NHS Scotland hospitals, enabling clinicians to compare new scans with prior studies irrespective of where they were performed in Scotland. It also allows the program’s regional screening centers to support one another – for example, when staff shortages limit the ability of any one center to cope with the volume of images that need to be read. As a result, patients benefit from faster diagnoses and better-informed treatment plans.

“This latest collaboration with the NHS in Scotland further demonstrates our commitment to deliver patient-centric solutions designed to deliver the right information at the right time to help improve the patient experience and help advance the path to precision care,” said Kees Wesdorp, Chief Business Leader of Precision Diagnosis at Philips. “The Scottish Breast Screening Program has revolutionized breast cancer care in Scotland, ensuring that no matter where patients live, they have a better chance of receiving an early diagnosis and timely treatment. Philips is proud to be working with the team at NHS Scotland to continually improve the technology, scope and scale of the program.”

Philips’ diagnostic informatics portfolio supports hospitals and imaging centers with intelligent, scalable, secure and interoperable solutions which connect people, technology and data to support clinical decisions at every point of care. Philips’ end-to-end portfolio of enterprise informatics solutions enables patients, clinicians and hospital administrators to fully harness the power of information and translate data into actionable insights – a critical next step to advance precision care.

Philips will be showcasing its enterprise imaging solutions that securely connect and facilitate the sharing of information among patients and their care teams across health systems at the upcoming HIMSS Global meeting, March 14 – March 18 in Orlando, Florida, USA. For more information on how the company’s advanced analytics and intelligent informatics support clinicians at the point-of-care by providing clinical insights and improving collaboration among clinical care teams, visit www.philips.com/himss and follow @PhilipsLiveFrom for #HIMSS22 updates throughout the event.

[1] Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764. https://pubmed.ncbi.nlm.nih.gov/33818764/
[2] https://www.nhsinform.scot/healthy-living/screening/breast/breast-screening
[3] https://www.isdscotland.org/Health-topics/Cancer/Breast-screening/
[4] https://publichealthscotland.scot/publications/cancer-staging-data-using-2018-to-2020-dce-data-the-impact-of-covid-19/cancer-staging-data-using-2018-to-2020-dce-data-the-impact-of-covid-19/

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Philips expands its Cybersecurity Services portfolio for healthcare providers

March 16, 2022

Integration of SecureLink critical access management technology with Philips Remote Services framework provides advanced security for remote technical and clinical support

Amsterdam, the Netherlands and Orlando, Florida, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the expansion of its medical device cybersecurity services portfolio at HIMSS22. Philips is introducing Secure Remote Access Management Service [1], leveraging the broad set of security capabilities enabled by the integration of SecureLink’s critical access management and governance technology with Philips Remote Services secure connectivity framework for technical and clinical support. The services provide benefits for healthcare providers including increased uptime, clinical performance, and advanced security to help protect access to their clinical solutions and medical devices.

“We are continuously expanding the foundation of Philips Cybersecurity Services and this type of integration is a strong complement to our offering, giving our customers more options for building robust cybersecurity programs,” said Gal Gnainsky, Head of Security at Philips. “As healthcare providers’ cybersecurity requirements continue to increase, partnering with SecureLink highlights Philips’ focus on offering best-in-class solutions to provide more secure access management and protect health networks down to granular device level.”

Philips Remote Services: a key enabler of digital transformation in healthcare
Remote services have become an essential component of the digital transformation of healthcare. Philips’ portfolio of remote services is utilized to monitor key performance parameters for many clinical systems and devices on a continuous basis and alert customers of potential issues and rectify them, often remotely, before they result in system or device failures that interrupt patient care. During the COVID-19 pandemic, they played an important role in helping to keep hospitals operational at a time when on-site maintenance was logistically difficult. Applying artificial intelligence (AI) and predictive analytics to the acquired data, they are also important to support the goals of zero system downtime, increased efficiency, and seamless uninterrupted workflows.

Secure access to combat increasing cyber threats in healthcare
By integrating with SecureLink’s vendor privileged access management and governance capabilities, the Philips Remote Services portfolio now provides additional capabilities, offering a uniform level of security, visibility, traceability, and audit capability needed for critical access management and data security. SecureLink’s solutions allow customers to manage privileged access sessions with rich audit logging, limiting access to relevant devices and systems and granting only ‘need to know’ permissions required to monitor or maintain them.

SecureLink is the industry leader in critical access management, empowering organizations to secure access to their most valuable assets, including networks, systems, and data. By partnering with Philips we are extending the web of security offered by our critical access management technology across their customer base and the healthcare ecosystem at large,” said Joel Burleson Davis, Chief Technology Officer of SecureLink. “With cybercrime in healthcare at an all-time high [2], partnerships like that between SecureLink and Philips are essential to protecting healthcare systems, data and patients from today’s increasingly sophisticated cyber threats.”

Security by design
The Philips Cybersecurity Services portfolio comprises an end-to-end suite of technologies and services to safeguard customers’ medical systems, devices, and related software regardless of vendor, helping empower the digital transformation in healthcare. The company’s approach to cybersecurity is characterized by end-to-end ‘Security by Design’ principles that focus on security during product design, development, testing, and deployment right through to in-use performance monitoring, system updates, and incident response management. Philips also contributes to the development of national and international cybersecurity standards for medical devices, and its Cybersecurity Services portfolio aligns with global cybersecurity best practices and standards. The Philips Remote Services operating environment implements security controls that meet the internationally recognized ISO/IEC 27001 Information Security Management Systems standard.

For more information on Philips’ full portfolio of connected informatics solutions being showcased in booth #2501 at the HIMSS22 Global Health Conference & Exhibition, please visit www.philips.com/himss and follow @PhilipsLiveFrom for #HIMSS22 updates throughout the event.

For Philips Product Security statement and white papers, click here.

[1] Philips Secure Remote Access Management Service will be available for selected Philips Remote Service enabled systems in the USA and Canada from Q3 2022. Philips will continue to expand Secure Remote Access Management Service to support more systems and remote service solutions.
[2] https://cybersecurity.criticalinsight.com/2021_H2_HealthcareDataBreachReport

For further information, please contact:

Anna Hogrebe
Philips Global Press Office
Tel.: +1 416 270 6757
E-Mail: anna.hogrebe@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Chargebee Launches Industry’s First E-Invoicing Service with Spring 2022 Product Release, Also Featuring Increased Automation Capabilities

Spring update to support tax, revenue recognition and regional compliance mandates to help customers expand globally

San Francisco, CA, March 16, 2022 (GLOBE NEWSWIRE) — Fresh off its recent round of funding, Chargebee, the leading subscription management platform, today announced the industry’s first e-invoicing service for high-performing SaaS and subscription-model businesses as the centerpiece of its Spring 2022 Product Release. The release includes updates geared towards enabling growth and efficiency for Chargebee customers, including taxation and revenue recognition features and a new Marketplace to automate billing workflows through a library of customizable integrations.

E-Invoicing

Countries across the world, including Brazil, France, Finland, Germany and India, are already mandating e-invoicing for Business to Government (B2G) transactions as a way of modernizing and simplifying tax reporting and payment and several countries, including Poland and France, will join Italy, Mexico and Chile in mandating e-invoicing for B2B transactions as early as 2023. Chargebee’s e-invoicing service will allow businesses seeking to expand operations globally to easily comply with local e-invoicing mandates and serve B2G and B2B customers in new regions.

“Chargebee has solved a huge problem for us,” said Gabriele Proni, co-founder and CTO of Voxloud, an Italian-based communications company. “Italy has some of the strictest e-invoicing mandates in the entire world, and without Chargebee’s e-invoicing service, we would have had to spend countless hours sending them out manually. Chargebee came in and helped automate the process, saving our team from spending unnecessary time and power and allowed us to focus on doing what we do best.”

Marketplace 

Automation is key to ensuring that modern billing systems are able to remain flexible and adaptable for businesses to succeed, especially for SaaS and subscription models, and is taking on a large role in Chargebee’s 2022 Spring Product Release.

Chargebee’s Marketplace enables businesses to build their billing systems on top of Chargebee, allowing for more and better integrations by connecting merchants with a wide catalog of available integrations to choose from. Marketplace improves integrations with other apps end-to-end, from discovery to sign-up, automating billing workflows and use cases.

Taxation and Revenue Recognition 

In addition to e-invoicing and Marketplace, Chargebee adds taxation and revenue recognition capabilities to handle real-time changes based on customer demands. Through automation, Chargebee is providing subscription businesses with a new way to sync billing information and improve an organization’s financial efficiency and enabling them to meet the growing list of compliance requirements, including Value-Added Tax (“VAT” in Europe) and Tax Deduction at Source (“TDS” in India).

Compliance

As Chargebee continues to support expansion into new and different geographies, customers need not worry about the growing list of regional and local compliances they will face. Chargebee is now certified as HIPAA compliant with the “Privacy Rule”, “Security Rule” and “Breach Notification” as per the HIPAA Portability and Accountability Act to support customers in the healthcare industry. In addition, Chargebee is also compliant with PCI and GDPR standards and adheres to ISO, SOC1, SOC2 and MFA standards.

Global Growth 

“Global and product expansion is a big part of Chargebee’s 2022-and-beyond roadmap, and we know that our customers are always looking to scale up, increase capabilities and enter new territories,” said John Pearce, Vice President of Product Management at Chargebee.  “There are tons of constantly changing rules and regulations that could inhibit growth, and our new offerings are designed to help our customers offload these concerns and focus on building and maintaining business.”

The Chargebee Spring 2022 Product Release full list of features includes:

  • E-invoicing for India and the European Union
  • Tax Withholding (TDS)
  • Subscriptions Marketplace
  • New Salesforce Integration UX
  • GST Breakdown (Australia)
  • Revenue Recognition through acquisition of RevLock
  • Retention through acquisition of Brightback
  • Receivables through acquisition of numberz
  • HIPAA Compliance
  • SOC-2 Compliance

These latest product enhancements come on the heels of a $250 million funding round that valued the company at $3.5 billion and was geared towards Chargebee’s global expansion. Recent acquisitions of Brightback (customer retention), RevLock (revenue recognition) and numberz (receivables) will also strengthen Chargebee’s offerings to enable end-to-end management of subscriptions and revenue data.

To learn more about Chargebee’s Spring 2022 Product Release, please visit https://www.chargebee.com/blog/spring-release-2022.

Penny Desatnik
Chargebee
penny@chargebee.com

Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial of VV116 in Treatment of Moderate to Severe COVID-19

SHANGHAI, China, March 16, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the first patient was dosed in its Phase III trial of VV116 for the treatment of moderate to severe COVID-19. The study is an international multicenter, randomized, double-blind, controlled Phase III study to evaluate the efficacy and safety of VV116 against standard therapy in subjects with moderate to severe COVID-19. The primary endpoint is the percentage of patients who progress to critical/severe COVID-19 patients or all-cause mortality within 29 days. VV116 is an oral nucleoside analog anti-SARS-CoV-2 investigational drug jointly developed by Junshi Biosciences and Vigonvita Life Sciences Co., Ltd. (“Vigonvita”).

In addition, Junshi Biosciences has also initiated an international multi-center, double-blind, randomized, placebo-controlled, phase II/III clinical study (NCT05242042) with Vigonvita, which aims to evaluate the efficacy, safety and pharmacokinetics of VV116 in the early treatment of mild to moderate COVID-19 patients. The primary endpoint is the percentage of patients who progress to critical/severe COVID-19 patients or all-cause mortality within 29 days. First patient of the study has been enrolled and dosed in China, and the study is being conducted in multiple centers around the world.

Junshi Biosciences and Vigonvita have completed three Phase I studies evaluating the safety, tolerability, and pharmacokinetics of VV116 in healthy Chinese subjects, with preliminary results showing good clinical safety. In addition, a randomized, open-label, controlled Phase II clinical trial of VV116 was completed in subjects with moderate to severe COVID-19 in Uzbekistan in 2021, which enrolled a total of about 450 subjects. Subjects were divided into two VV116 groups (200mg and 300mg doses of VV116 orally, twice daily for 5 days) and one control group of standard therapy, with each group of about 150 subjects. The results of the study indicate that the two different doses of VV116 showed favorable safety and efficacy in the treatment of both moderate and severe COVID-19 patients, in comparison with standard therapy. Based on the positive results, VV116 has been approved for the treatment of moderate to severe COVID-19 patients in Uzbekistan in late 2021.

About VV116

VV116 is a new oral nucleoside analog anti-SARS-CoV-2 drug that inhibits the replication of SARS-CoV-2. Preclinical studies have shown that VV116 exhibited significant anti-SARS-CoV-2 effects in vivo and in vitro, had antiviral activity against both the original strain of SARS- CoV-2 and the major known variants (Alpha, Beta, Delta, and Omicron), and exhibited high oral bioavailability and good chemical stability.

VV116 is jointly developed by three institutes of the Chinese Academy of Sciences (Shanghai Institute of Materia Medica, Wuhan Institute of Virology, and Xinjiang Technical Institute of Physics and Chemistry), Central Asian Center of Drug Discovery and Development of Chinese Academy of Sciences/China-Uzbekistan Medicine Technical Park (the Belt and Road Joint Laboratory of the Ministry of Science and Technology), Vigonvita, and Junshi Biosciences. In September 2021, Junshi Biosciences entered into a collaboration with Vigonvita to jointly undertake the clinical development and commercialization of VV116 in the cooperation territory (worldwide except five Central Asian countries (Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan, Turkmenistan), Russia, North Africa (Egypt, Libya, Tunisia, Algeria, Morocco, Sudan), and the Middle East (19 countries including Saudi Arabia, Iran, Iraq, Turkey, Israel, etc.)).

VV116 has been approved for treatment of moderate to severe COVID-19 patients in Uzbekistan.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising over 45 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in more than 15 countries and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@gobyglobal.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800